MX340272B - Composicion sinergica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composicion para el tratamiento de la parasitosis humana. - Google Patents

Composicion sinergica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composicion para el tratamiento de la parasitosis humana.

Info

Publication number
MX340272B
MX340272B MX2015003941A MX2015003941A MX340272B MX 340272 B MX340272 B MX 340272B MX 2015003941 A MX2015003941 A MX 2015003941A MX 2015003941 A MX2015003941 A MX 2015003941A MX 340272 B MX340272 B MX 340272B
Authority
MX
Mexico
Prior art keywords
ntzx
mbdz
synergic
composition
treatment
Prior art date
Application number
MX2015003941A
Other languages
English (en)
Other versions
MX2015003941A (es
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50387067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340272(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of MX2015003941A publication Critical patent/MX2015003941A/es
Publication of MX340272B publication Critical patent/MX340272B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica sinérgica para el tratamiento de parasitosis humana de Mebendazol (MBDZ) con Nitazoxanida (NTZX), que amplía significativamente el espectro del MBDZ contra protozoos y refuerza la acción antihelmíntica de la NTZX. Además, al usar dicha combinación farmacéutica de MBDZ y NTZX, la acción sistémica del metabolito activo de la NTZX, la Tizoxanida, y el tratamiento de algunas formas sistémicas de parasitosis, mantienen los mismos efectos de los principios activos individuales. También, la combinación farmacéutica sinérgica de MBDZ con NTZX logra un mayor espectro antiparasitario, mientras mantienen la eficacia y los perfiles de seguridad de ambos principios activos por separado. Todos estos efectos permiten que la combinación farmacéutica de la presente invención se diferencie del resto de los tratamientos antiparasitarios clásicos que tienen espectros más acotados. Los efectos sinérgicos de la combinación farmacéutica MBDZ y NTZX son, por consiguiente, el objeto principal de la presente invención.
MX2015003941A 2012-09-27 2012-09-27 Composicion sinergica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composicion para el tratamiento de la parasitosis humana. MX340272B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/055166 WO2014049397A1 (es) 2012-09-27 2012-09-27 Composición sinérgica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composición para el tratamiento de la parasitosis humana

Publications (2)

Publication Number Publication Date
MX2015003941A MX2015003941A (es) 2015-07-21
MX340272B true MX340272B (es) 2016-06-30

Family

ID=50387067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003941A MX340272B (es) 2012-09-27 2012-09-27 Composicion sinergica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composicion para el tratamiento de la parasitosis humana.

Country Status (10)

Country Link
US (1) US20150250765A1 (es)
EP (1) EP2902024B1 (es)
AR (1) AR092169A1 (es)
BR (1) BR112015006861B1 (es)
CL (1) CL2015000778A1 (es)
CR (1) CR20150190A (es)
MX (1) MX340272B (es)
NI (1) NI201500045A (es)
UY (1) UY34967A (es)
WO (1) WO2014049397A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2610791B1 (es) * 2016-12-22 2018-02-07 Elena TEIJEIRA PRIETO Uso del mebendazol para la eliminación de los gusanos de fuego en acuarios de arrecife
CN111494327B (zh) * 2020-06-23 2023-09-05 瑞阳制药股份有限公司 甲苯咪唑咀嚼片的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657267A (en) 1969-06-20 1972-04-18 Janssen Pharmaceutica Nv Benzimidazole carbamates
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US20050171169A1 (en) * 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby

Also Published As

Publication number Publication date
EP2902024A1 (en) 2015-08-05
BR112015006861B1 (pt) 2021-10-13
MX2015003941A (es) 2015-07-21
CL2015000778A1 (es) 2015-08-21
BR112015006861A2 (pt) 2017-07-04
EP2902024A4 (en) 2016-06-22
CR20150190A (es) 2015-07-09
EP2902024B1 (en) 2017-11-29
WO2014049397A1 (es) 2014-04-03
UY34967A (es) 2014-04-30
AR092169A1 (es) 2015-03-25
US20150250765A1 (en) 2015-09-10
NI201500045A (es) 2016-02-16

Similar Documents

Publication Publication Date Title
GB201118656D0 (en) New compounds
MX2017007321A (es) Terapias de combinacion.
MX366899B (es) Nuevos compuestos.
EP4140487A8 (en) Combination therapy for treating cancer
WO2014062720A3 (en) Methods of treating cancer
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
GB201209613D0 (en) New compounds
MX365702B (es) Inhibidores de pirazolil quinoxalina cinasa.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
GB201316021D0 (en) Vitamin D composition
MX340985B (es) Compuestos de n-heteroarilo.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
WO2013185764A3 (en) Pharmaceutical compositions for combination therapy
BR112017009510A2 (pt) composições compreendendo ciclosporina
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX340272B (es) Composicion sinergica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composicion para el tratamiento de la parasitosis humana.
EP3449920A4 (en) COMPOSITION USING NAPHTHOCHINONE - BASED COMPOUND AS ACTIVE AGENT FOR PREVENTING OR PREVENTING TEMPERATURE, CACHEXIA, PAIN, COGNITIVE DECONTAMINATION AND REDUCTION OF HEMATOPOETIC STEM CELLS AS SIDE EFFECTS RELATED TO A MEDICAMENTAL OIL CANCER TREATMENT
EP3417869A4 (en) COMPOSITION CONTAINING RHIZOMA PHRAGMITIS EXTRACT AS AN ACTIVE INGREDIENT FOR PREVENTING, IMPROVING OR TREATING DISEASES AFFECTED BY ANTI-CANCER AGENT'S SECONDARY EFFECT

Legal Events

Date Code Title Description
FG Grant or registration